Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
All content for Oncology Decoded is the property of Oncology Decoded and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
8: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management
Oncology Decoded
50 minutes
6 months ago
8: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.
Oncology Decoded
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
